- Home
- INVE vs IMUX Comparison
INVE vs IMUX Comparison
Compare INVE & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- IMUX
- Stock Information
- Founded
- INVE 1990
- IMUX 2016
- Country
- INVE United States
- IMUX United States
- Employees
- INVE N/A
- IMUX N/A
- Industry
- INVE Computer peripheral equipment
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- IMUX Health Care
- Exchange
- INVE Nasdaq
- IMUX Nasdaq
- Market Cap
- INVE 85.9M
- IMUX 92.2M
- IPO Year
- INVE 1997
- IMUX N/A
- Fundamental
- Price
- INVE $3.86
- IMUX $0.78
- Analyst Decision
- INVE Strong Buy
- IMUX Strong Buy
- Analyst Count
- INVE 2
- IMUX 5
- Target Price
- INVE $5.50
- IMUX $7.00
- AVG Volume (30 Days)
- INVE 33.8K
- IMUX 1.5M
- Earning Date
- INVE 11-06-2025
- IMUX 11-06-2025
- Dividend Yield
- INVE N/A
- IMUX N/A
- EPS Growth
- INVE N/A
- IMUX N/A
- EPS
- INVE 3.12
- IMUX N/A
- Revenue
- INVE $23,538,000.00
- IMUX N/A
- Revenue This Year
- INVE N/A
- IMUX N/A
- Revenue Next Year
- INVE $9.06
- IMUX N/A
- P/E Ratio
- INVE $1.21
- IMUX N/A
- Revenue Growth
- INVE N/A
- IMUX N/A
- 52 Week Low
- INVE $2.86
- IMUX $0.56
- 52 Week High
- INVE $4.29
- IMUX $1.42
- Technical
- Relative Strength Index (RSI)
- INVE 53.92
- IMUX 41.54
- Support Level
- INVE $3.78
- IMUX $0.78
- Resistance Level
- INVE $4.07
- IMUX $0.87
- Average True Range (ATR)
- INVE 0.20
- IMUX 0.05
- MACD
- INVE 0.01
- IMUX -0.01
- Stochastic Oscillator
- INVE 67.63
- IMUX 16.15
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.